References
- Md Shah A. Adverse drug reactions and pharmacovigilance. In Herdeiro MT, Roque F, Figueiras A, editors. New insights into the future of pharmacoepidemiology and drug safety. London: IntechOpen; 2021.
- Bouvy J, Bruin M, Koopmanschap M. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–453.
- Editorial. Improving ADR reporting. Lancet. 2002;9(9344):1435.
- Hussain R, Hassali MA, Hashmi F, et al. A qualitative exploration of knowledge, attitudes and practices of hospital pharmacists towards adverse drug reaction reporting system in Lahore. J Pharm Policy Pract. 2018;11(16):16.
- World Health Organisation. Pharmacovigilance (WHO). [Internet] 2002. [cited 2021 Mar 8]. Available from: https://www.who.int/teams/regulation-prequalification/regulation-andsafety/pharmacovigilance.
- Medicines and Medical Devices Agency of Serbia (ALIMS). [cited 2021 Jan 17]. Available from: https://www.alims.gov.rs/eng/pharmacovigilance/marketing-authorizationholders/.
- European Medical Agency (EMA). Pharmacovigilance: overview. [cited 2021 Aug 3]. Available from: https://www.ema.europa.eu/en/humanregulatory/overview/pharmacovigilance-overview.
- Food and Drug Administration (FDA). Postmarketing Adverse Event Reporting Compliance Program. [cited 2021 Aug 3]. Available from: https://www.fda.gov/drugs/surveillance/postmarketing-adverse-event-reporting-compliance-program.
- Li R, Curtain C, Bereznicki L, et al. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018;40(4):878–889.
- Kopciuch D, Zaprutko T, Paczkowska A, et al. Safety of medicines-pharmacists’ knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Pharmacoepidemiol Drug Saf. 2019;28(12):1543–1551.
- Granas AG, Buajordet M, Stenberg-Nilsen H, et al. Pharmacists’ attitudes towards the reporting of suspected adverse drug reactions in Norway. Pharmacoepidem Drug Saf. 2007;16(4):429–434.
- Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19(3):217–222.
- Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci. 2008;30(5):556–562.
- Vessal G, Mardani Z, Mollai M. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci. 2009;31(2):183–187.
- Suyagh M, Farah D, Farha RA. Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharm J. 2015;23(2):147–153.
- Oreagba IA, Ogunleye OJ, Olayemi SO. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, South West Nigeria. Pharmacoepidemiol Drug Saf. 2011;20(1):30–35.
- Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2012;29(5):385–396.
- Onakpoya IJ, Heneghan CJ, Aronson JK. Postmarketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14(1):10.
- Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681–695.
- Kongkaew C, Hann M, Mandal J, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33(8):827–837.
- Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond. 1995;29(1):41–49.
- Medicines and Medical Devices Agency of Serbia. Pharmacovigilance. [cited 2021 Jan 17]. Available from: https://www.alims.gov.rs/eng/pharmacovigilance/.
- Medicines and Medical Devices Agency of Serbia. Annual report on reporting adverse drug reactions in Republic of Serbia. 2019. [cited 2021 Apr 17]. Available from: https://www.alims.gov.rs/ciril/files/2020/06/Godi%C5%A1nji-izve%C5%A1taj-oprijavljivanju-NRL-2019.pdf.
- Medicines and Medical Devices Agency of Serbia. Pharmacovigilance. [cited 2021 Oct 10]. Available from: https://www.alims.gov.rs/eng/pharmacovigilance/reporting-of-adverse-drug-reactions/.
- Li R, Zaidi ST, Chen T, et al. Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: a systematic review. Pharmacoepidemiol Drug Saf. 2020;29(1):1–8.
- Shalviri G, Mohebbi N, Mirbaha F, et al. Improving adverse drug event reporting by health care professionals. Cochrane Database Syst Rev. 2017;2017(3):CD012594.
- Correa E, Jauregui OI, Frangella J, et al. Adverse drug event reporting rates after the implementation of an EHR integrated reporting system. Stud Health Technol Inform. 2019;264:1652–1653.
- Paudyal V, Al-Hamid A, Bowen M, et al. Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(9):1173–1191.
- Alshayban D, Mahmoud MA, Islam MA, et al. Pharmacovigilance perception and knowledge among pharmacists and interns in Saudi Arabia. Risk Manag Healthc Policy. 2020;13:55–61.
- Mahmoud MA, Alswaida Y, Alshammari T, et al. Community pharmacist’s knowledge, behaviours and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J. 2014;22(5):411–418.
- The pharmaceutical Chamber of Serbia. [cited 2021 May 17]. Available from: https://www.farmkom.rs/baze-podataka.phd.
- Determining sample size: how to make sure you get the correct sample size. [cited 2021 Jan 17]. Available from: https://www.qualtrics.com/experience-management/research/determine-sample-size.
- Kaiser HF. The varimax criterion for analytic rotation in factor analysis. Psychometrika. 1958;23(3):187–200.
- Medicines and Medical Devices Agency of Serbia. [cited 2021 Jan 17]. Available from: https://www.alims.gov.rs/latin/2017/11/29/obavestenje-14/.
- Meestere DD, Saevels J. Belgian community pharmacists’ pharmacovigilance perspective and practice. Res Social Adm Pharm. 2019;15(12):1446–1452.
- Hughes ML, Weiss M. Adverse drug reaction reporting by community pharmacists – the barriers and facilitators. Pharmacoepidemiol Drug Saf. 2019;28(12):1552–1559.
- Aldryhim AY, Alomair A, Alqhtani M, et al. Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Expert Opin Drug Saf. 2019;18(8):745–752.